Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure.
Right ventricular failure (RVF) is the leading cause of death in pulmonary arterial hypertension (PAH). Some patients with pulmonary hypertension are adaptive remodelers and develop RV hypertrophy (RVH) but retain RV function; others are maladaptive remodelers and rapidly develop RVF. The cause of RVF is unclear and understudied and most PAH therapies focus on regressing pulmonary vascular disease. Studies in animal models and human RVH suggest that there is reduced glucose oxidation and increased glycolysis in both adaptive and maladaptive RVH. The metabolic shift from oxidative mitochondrial metabolism to the less energy efficient glycolytic metabolism may reflect myocardial ischemia. We hypothesize that in maladaptive RVH a vicious cycle of RV ischemia and transcription factor activation causes a shift from oxidative to glycolytic metabolism thereby ultimately promoting RVF. Interrupting this cycle, by reducing ischemia or enhancing glucose oxidation, might be therapeutic. Dichloroacetate, a pyruvate dehydrogenase kinase inhibitor, has beneficial effects on RV function and metabolism in experimental RVH, notably improving glucose oxidation and enhancing RV function. This suggests the mitochondrial dysfunction in RVH may be amenable to therapy. In this mini review, we describe the role of impaired mitochondrial metabolism in RVH, using rats with adaptive (pulmonary artery banding) or maladaptive (monocrotaline-induced pulmonary hypertension) RVH as models of human disease. We will discuss the possible mechanisms, relevant transcriptional factors, and the potential of mitochondrial metabolic therapeutics in RVH and RVF.
Piao
Lin
L
Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL, USA.
Marsboom
Glenn
G
Archer
Stephen L
SL
D000222:Adaptation, Physiological / Q000502:physiology*; D000818:Animals; D005227:Fatty Acids / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D017380:Hypertrophy, Right Ventricular / Q000503:physiopathology*; D008928:Mitochondria / Q000502:physiology*; D010084:Oxidation-Reduction; D010100:Oxygen / Q000378:metabolism
D005227:Fatty Acids; D005947:Glucose; D010100:Oxygen
Heart Vessels. 2009 Jul;24(4):277-82
19626400
Am J Physiol. 1997 Jun;272(6 Pt 2):H2833-42
9227563
Nat Rev Cancer. 2008 Jan;8(1):51-6
18046334
Am J Physiol. 1999 Nov;277(5):H1725-31
10564125
Acta Pharmacol Sin. 2004 Feb;25(2):226-30
14769214
Circulation. 2002 Jan 15;105(2):244-50
11790708
Expert Opin Investig Drugs. 2002 May;11(5):615-29
11996644
Circ Res. 2000 Mar 17;86(5):580-8
10720420
Cardiovasc Res. 1991 Sep;25(9):731-9
1839241
Eur Heart J. 2007 May;28(10):1250-7
17242010
Ann Nucl Med. 1997 Aug;11(3):207-12
9310169
Kardiol Pol. 2008 Oct;66(10):1033-9; discussion 1040-1
19006024
Cardiovasc Res. 1997 Feb;33(2):243-57
9074687
Am J Physiol. 1970 Jan;218(1):153-9
4243400
Cardiol J. 2008;15(4):344-50
18698543
Cardiovasc Res. 2003 Jul 1;59(1):143-51
12829185
J Am Coll Cardiol. 2005 Jun 7;45(11):1849-55
15936618
J Mol Med (Berl). 2010 Jan;88(1):47-60
19949938
J Exp Biol. 2004 Aug;207(Pt 18):3189-200
15299040
EMBO J. 2006 Aug 23;25(16):3869-79
16902412
J Electrocardiol. 2005 Oct;38(4 Suppl):154-8
16226092
Am J Physiol. 1998 Dec;275(6):H1948-56
9843792
Physiol Genomics. 2005 May 11;21(3):314-23
15728335
Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1107-14
17496214
Europace. 2007 Sep;9 Suppl 4:iv4-15
17766323
Nat Clin Pract Cardiovasc Med. 2006 Sep;3(9):490-8
16932766
Circulation. 2009 Nov 17;120(20):1951-60
19884466
J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S169-S177
16686675
J Cardiovasc Pharmacol. 1996 Sep;28(3):353-62
8877580
J Thorac Cardiovasc Surg. 2008 Jul;136(1):168-78, 178.e1-3
18603070
Am J Physiol. 1998 Jul;275(1):H169-75
9688910
Eur Respir J. 2010 Jun;35(6):1286-93
19897557
Circulation. 2008 Sep 16;118(12):1250-8
18765391
Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1185-92
14630626
Cardiovasc Diabetol. 2003 Nov 28;2:16
14641923
J Am Coll Cardiol. 2001 Oct;38(4):1137-42
11583894
Eur Heart J. 2008 Jan;29(1):120-7
18065750
J Mol Cell Cardiol. 1996 Feb;28(2):341-50
8729066
Ann Nucl Med. 2007 Dec;21(10):569-76
18092133
J Clin Invest. 2010 Jan;120(1):142-56
20038799
Annu Rev Physiol. 1974;36:413-59
19400669
J Cell Biochem. 1994 Jan;54(1):78-84
8126088
J Pharmacol Sci. 2009 Sep;111(1):33-43
19763046
J Heart Lung Transplant. 1997 Jul;16(7):774-85
9257260
Circulation. 1981 Jan;63(1):87-95
7438411
J Mol Cell Cardiol. 1997 Jul;29(7):1903-13
9236144
Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H1038-47
20061549
Heart Fail Rev. 2007 Dec;12(3-4):331-43
17516164
Curr Clin Pharmacol. 2007 Sep;2(3):190-6
18690865
Circulation. 1996 Jan 1;93(1):135-42
8616920
Cardiovasc Res. 2007 Sep 1;75(4):770-81
17582388
J Pharmacol Exp Ther. 2007 Apr;321(1):213-20
17202401
Biochem J. 2000 Dec 15;352 Pt 3:731-8
11104680